Aditxt's Target Acquisition Appili Therapeutics Announces Alignment With FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Businesswire10/31 20:30

Appili Therapeutics Announces "Alignment" With FDA on ATI-1801 Development Requirements

MT Newswires10/31 19:57

Appili Therapeutics – Press Release Correction

GlobeNewswire10/11 03:40

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire09/18 05:11

Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction With Aditxt

GlobeNewswire08/21 19:15

Appili Therapeutics Brief: Says Definitive Agreement With Aditxt, If Approved by Appili Shareholders, "Provides Significant Premium to Shareholders and Resources to Advance Key Programs"

MT Newswires08/14 05:30